{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:04:23Z","timestamp":1790996663698,"version":"4.1.0"},"reference-count":75,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T00:00:00Z","timestamp":1418688000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114086","type":"journal-article","created":{"date-parts":[[2014,12,16]],"date-time":"2014-12-16T18:46:51Z","timestamp":1418755611000},"page":"e114086","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Unprecedented Therapeutic Potential with a Combination of A2A\/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease"],"prefix":"10.1371","volume":"9","author":[{"given":"Anne","family":"Michel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Downey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson&apos;s disease: mechanisms and models","volume":"39","author":"W Dauer","year":"2003","journal-title":"Neuron"},{"key":"ref2","first-page":"1605","article-title":"Levodopa-induced dyskinesias in Parkinson&apos;s disease: emerging treatments","volume":"9","author":"P Bargiotas","year":"2013","journal-title":"NeuropsychiatrDisTreat"},{"key":"ref3","first-page":"93","article-title":"Treatment of motor fluctuations in Parkinson&apos;s disease: recent developments and future directions","volume":"14","author":"A Ramirez-Zamora","year":"2014","journal-title":"ExpertRevNeurother"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/mds.21611","article-title":"Pathological gambling in Parkinson&apos;s disease: risk factors and differences from dopamine dysregulation. An analysis of published case series","volume":"22","author":"DA Gallagher","year":"2007","journal-title":"Mov Disord"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of L-DOPA-induced dyskinesia","volume":"9","author":"P Jenner","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2008.09.013","article-title":"Priming for l-dopa-induced dyskinesia in Parkinson&apos;s disease: a feature inherent to the treatment or the disease?","volume":"87","author":"A Nadjar","year":"2009","journal-title":"Prog Neurobiol"},{"key":"ref7","first-page":"277","article-title":"Adenosine A2A receptors and basal ganglia physiology","volume":"83","author":"SN Schiffmann","year":"2007","journal-title":"ProgNeurobiol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1471-4159.1991.tb08257.x","article-title":"Striatal restricted adenosine A2 receptor (RDC8) is expressed by enkephalin but not by substance P neurons: an in situ hybridization histochemistry study","volume":"57","author":"SN Schiffmann","year":"1991","journal-title":"J Neurochem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0169-328X(92)90173-9","article-title":"Molecular cloning of the rat A2 adenosine receptor: selective co-expression with D2 dopamine receptors in rat striatum","volume":"14","author":"JS Fink","year":"1992","journal-title":"Brain ResMolBrain Res"},{"key":"ref10","first-page":"209","article-title":"Adenosine A2A and dopamine D2 heteromeric receptor complexes and their function","volume":"26","author":"K Fuxe","year":"2005","journal-title":"JMolNeurosci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"10808","DOI":"10.1523\/JNEUROSCI.1661-06.2006","article-title":"Blockade of adenosine A2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation","volume":"26","author":"C Quiroz","year":"2006","journal-title":"JNeurosci"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","article-title":"Targeting adenosine A2A receptors in Parkinson&apos;s disease","volume":"29","author":"MA Schwarzschild","year":"2006","journal-title":"Trends Neurosci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1353-8020(00)00063-8","article-title":"Adenosine\/dopamine interaction: implications for the treatment of Parkinson&apos;s disease","volume":"7","author":"S Ferre","year":"2001","journal-title":"ParkinsonismRelat Disord"},{"key":"ref14","first-page":"285","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson&apos;s disease","volume":"184","author":"F Bibbiani","year":"2003","journal-title":"ExpNeurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/1098-2396(20010301)39:3<233::AID-SYN1004>3.0.CO;2-K","article-title":"Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats","volume":"39","author":"A Pinna","year":"2001","journal-title":"Synapse"},{"key":"ref16","first-page":"8104","article-title":"In vivo characterization of a dual adenosine A2A\/A1 receptor antagonist in animal models of Parkinson&apos;s disease","volume":"53","author":"BC Shook","year":"2010","journal-title":"JMedChem"},{"key":"ref17","first-page":"1176","article-title":"Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats","volume":"8","author":"A Pinna","year":"1996","journal-title":"EurJNeurosci"},{"key":"ref18","first-page":"157","article-title":"New adenosine A2A receptor antagonists: actions on Parkinson&apos;s disease models","volume":"512","author":"A Pinna","year":"2005","journal-title":"EurJPharmacol"},{"key":"ref19","first-page":"94","article-title":"Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats","volume":"566","author":"E Tronci","year":"2007","journal-title":"EurJPharmacol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1124\/jpet.108.149617","article-title":"Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazol o[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression","volume":"330","author":"RA Hodgson","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Atack JR, Shook BC, Rassnick S, Jackson PF, Rhodes K, <etal>et al<\/etal>. (2014) JNJ-40255293, A Novel Adenosine A2A\/A1 Antagonist With Efficacy In Preclinical Models of Parkinson&apos;s Disease. ACS ChemNeurosci.","DOI":"10.1021\/cn5001606"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2009.06.008","article-title":"Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial","volume":"16","author":"HH Fernandez","year":"2010","journal-title":"ParkinsonismRelat Disord"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S1474-4422(14)70148-6","article-title":"Tozadenant (SYN115) in patients with Parkinson&apos;s disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial","volume":"13","author":"RA Hauser","year":"2014","journal-title":"Lancet Neurol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","article-title":"A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease","volume":"70","author":"M Stacy","year":"2008","journal-title":"Neurology"},{"key":"ref25","first-page":"295","article-title":"Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson&apos;s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005)","volume":"63","author":"PA Lewitt","year":"2008","journal-title":"AnnNeurol"},{"key":"ref26","unstructured":"Co.Ltd KHK (2013) Launch of NOURIAST tablets 20 mg, in Japan, a novel antiparkinsonian agent. In: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/kyowa-kirin.com\/news_releases\/2013\/e20130529_01.html\" xlink:type=\"simple\">http:\/\/kyowa-kirin.com\/news_releases\/2013\/e20130529_01.html<\/ext-link>, editors."},{"key":"ref27","first-page":"73","article-title":"Glutamate and Parkinson&apos;s disease","volume":"12","author":"F Blandini","year":"1996","journal-title":"MolNeurobiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson&apos;s disease","volume":"102","author":"PJ Hallett","year":"2004","journal-title":"Pharmacol Ther"},{"key":"ref29","first-page":"1017","article-title":"Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson&apos;s disease","volume":"26","author":"S Duty","year":"2012","journal-title":"CNSDrugs"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2165\/00002512-200320050-00006","article-title":"Glutamate receptors and Parkinson&apos;s disease: opportunities for intervention","volume":"20","author":"MJ Marino","year":"2003","journal-title":"Drugs Aging"},{"key":"ref31","first-page":"55","article-title":"The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications","volume":"97","author":"JM Loftis","year":"2003","journal-title":"PharmacolTher"},{"key":"ref32","first-page":"185","article-title":"Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia","volume":"23","author":"MJ Marino","year":"2002","journal-title":"AminoAcids"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0022-3565(24)35003-7","article-title":"Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys","volume":"290","author":"PJ Blanchet","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonian activity of Ro 25\u20136981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson&apos;s disease","volume":"187","author":"PA Loschmann","year":"2004","journal-title":"Exp Neurol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/exnr.1998.6963","article-title":"Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat","volume":"155","author":"JE Nash","year":"1999","journal-title":"Exp Neurol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1006\/exnr.2000.7444","article-title":"Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson&apos;s disease","volume":"165","author":"JE Nash","year":"2000","journal-title":"Exp Neurol"},{"key":"ref37","first-page":"239","article-title":"Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors","volume":"163","author":"K Steece-Collier","year":"2000","journal-title":"ExpNeurol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.expneurol.2004.05.004","article-title":"The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson&apos;s disease","volume":"188","author":"JE Nash","year":"2004","journal-title":"Exp Neurol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2004.03.011","article-title":"NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats","volume":"47","author":"RH Wessell","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/(SICI)1096-9861(20000417)419:4<407::AID-CNE1>3.0.CO;2-I","article-title":"Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum","volume":"419","author":"KD Kuppenbender","year":"2000","journal-title":"J Comp Neurol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/mds.22169","article-title":"Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism","volume":"23","author":"JG Nutt","year":"2008","journal-title":"Mov Disord"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1177\/0091270009336735","article-title":"Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson&apos;s disease","volume":"49","author":"C Addy","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"7782","DOI":"10.1523\/JNEUROSCI.20-20-07782.2000","article-title":"A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson&apos;s disease","volume":"20","author":"JE Nash","year":"2000","journal-title":"J Neurosci"},{"key":"ref44","article-title":"Separate intramolecular targets for protein kinase A control of N-methyl-D-aspartate receptor gating and Ca2+ permeability","author":"TK Aman","year":"2014","journal-title":"JBiolChem"},{"key":"ref45","first-page":"501","article-title":"Protein kinase A regulates calcium permeability of NMDA receptors","volume":"9","author":"VA Skeberdis","year":"2006","journal-title":"NatNeurosci"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.neuropharm.2007.05.018","article-title":"Regulation of NMDA receptors by phosphorylation","volume":"53","author":"BS Chen","year":"2007","journal-title":"Neuropharmacology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-201X.1971.tb11000.x","article-title":"Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system","volume":"367","author":"U Ungerstedt","year":"1971","journal-title":"Acta Physiol Scand Suppl"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/0006-8993(70)90187-3","article-title":"Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system","volume":"24","author":"U Ungerstedt","year":"1970","journal-title":"Brain Res"},{"key":"ref49","first-page":"352","article-title":"Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists","volume":"2","author":"ME Layton","year":"2011","journal-title":"ACS ChemNeurosci"},{"key":"ref50","first-page":"708","article-title":"Pharmacological characterization of a novel, potent adenosine A1 and A2A receptor dual antagonist, 5-[5-amino-3-(4-fluorophenyl)pyrazin-2-yl]-1-isopropylpyridine-2(1H)-one (ASP5854), in models of Parkinson&apos;s disease and cognition","volume":"323","author":"T Mihara","year":"2007","journal-title":"JPharmacolExpTher"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00213-008-1319-0","article-title":"The effects of systemic, intrastriatal, and intrapallidal injections of caffeine and systemic injections of A2A and A1 antagonists on forepaw stepping in the unilateral 6-OHDA-lesioned rat","volume":"201","author":"JE Kelsey","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1046\/j.1471-4159.2003.01632.x","article-title":"Cellular and behavioural effects of the adenosine A2a receptor antagonist KW-6002 in a rat model of l-DOPA-induced dyskinesia","volume":"84","author":"M Lundblad","year":"2003","journal-title":"J Neurochem"},{"key":"ref53","first-page":"219","article-title":"A within-subjects microdialysis\/behavioural study of the role of striatal acetylcholine in D1-dependent turning","volume":"103","author":"E Acquas","year":"1999","journal-title":"BehavBrain Res"},{"key":"ref54","first-page":"514","article-title":"Differential susceptibility to the PPAR-gamma agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson&apos;s disease","volume":"65","author":"C Laloux","year":"2012","journal-title":"PharmacolRes"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00213-004-1799-5","article-title":"NMDA receptor antagonists ameliorate the stepping deficits produced by unilateral medial forebrain bundle injections of 6-OHDA in rats","volume":"175","author":"JE Kelsey","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"ref56","unstructured":"Michel A, Christophe B (2008) Comparison of the activity of three NR2B antagonists, Ro 25\u20136981, Co 101244 and 20J in experimental models of Parkinson&apos;s disease. Society for Neuroscience, Abstract 742."},{"key":"ref57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0301-0082(96)00040-8","article-title":"The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments","volume":"50","author":"RK Schwarting","year":"1996","journal-title":"Prog Neurobiol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.bbr.2003.10.009","article-title":"Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias","volume":"152","author":"MA Delfino","year":"2004","journal-title":"Behav Brain Res"},{"key":"ref59","first-page":"143","article-title":"Nicotine and epibatidine alter differently nomifensine-elevated dopamine output in the rat dorsal and ventral striatum","volume":"511","author":"S Janhunen","year":"2005","journal-title":"EurJPharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00213-006-0680-0","article-title":"Postsynaptic 5-HT1A receptor stimulation increases motor activity in the 6-hydroxydopamine-lesioned rat: implications for treating Parkinson&apos;s disease","volume":"192","author":"L Mignon","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"ref61","first-page":"179","article-title":"The adenosine receptor antagonist theophylline induces a monoamine-dependent increase of the anticataleptic effects of NMDA receptor antagonists","volume":"354","author":"W Hauber","year":"1996","journal-title":"Naunyn Schmiedebergs ArchPharmacol"},{"key":"ref62","first-page":"S111","article-title":"Lack of pharmacokinetic (PK) effect of preladenant as a perpetrator of probe drug-drug interactions","volume":"93","author":"J Udo de Haes","year":"2013","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"ref63","first-page":"1092","article-title":"A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson&apos;s disease, and atorvastatin","volume":"48","author":"N Rao","year":"2008","journal-title":"JClinPharmacol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"e16088","DOI":"10.1371\/journal.pone.0016088","article-title":"Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists","volume":"6","author":"M Orru","year":"2011","journal-title":"PLoSOne"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Pinna A (2014) Adenosine A Receptor Antagonists in Parkinson&apos;s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued. CNSDrugs.","DOI":"10.1007\/s40263-014-0161-7"},{"key":"ref66","first-page":"1357","article-title":"Animal models of Parkinson&apos;s disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"S Duty","year":"2011","journal-title":"BrJPharmacol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1474-4422(08)70214-X","article-title":"Non-dopaminergic treatments in development for Parkinson&apos;s disease","volume":"7","author":"SH Fox","year":"2008","journal-title":"Lancet Neurol"},{"key":"ref68","first-page":"1472","article-title":"Present and future drug treatment for Parkinson&apos;s disease","volume":"76","author":"AH Schapira","year":"2005","journal-title":"JNeurolNeurosurgPsychiatry"},{"key":"ref69","first-page":"1301","article-title":"Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential","volume":"157","author":"L Mony","year":"2009","journal-title":"BrJPharmacol"},{"key":"ref70","first-page":"475","article-title":"Glutamate receptors as therapeutic targets for Parkinson&apos;s disease","volume":"8","author":"KA Johnson","year":"2009","journal-title":"CNSNeurolDisordDrug Targets"},{"key":"ref71","first-page":"280","article-title":"Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson&apos;s disease","volume":"132","author":"MT Armentero","year":"2011","journal-title":"PharmacolTher"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/PL00005326","article-title":"Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors","volume":"359","author":"E Ongini","year":"1999","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.bmcl.2006.11.083","article-title":"Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines","volume":"17","author":"BR Neustadt","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1021\/jm990246i","article-title":"4-Hydroxy-1-[2-(4-hydroxyphenoxy)ethyl]-4-(4-methylbenzyl)piperidine: a novel, potent, and selective NR1\/2B NMDA receptor antagonist","volume":"42","author":"ZL Zhou","year":"1999","journal-title":"J Med Chem"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1016\/j.bmcl.2004.05.053","article-title":"Oxamides as novel NR2B selective NMDA receptor antagonists","volume":"14","author":"G Barta-Szalai","year":"2004","journal-title":"Bioorg Med Chem Lett"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T03:33:40Z","timestamp":1747193620000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114086"}},"subtitle":[],"editor":[{"given":"Joohyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,16]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114086","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,16]]}}}